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Adjuvant therapy has improved the survival of women with early breast cancer (BC). Meta-analyses suggest that
anthracycline-based regimens reduced the annual BC death rate by 40% in women below the age of 50 and 20% in
older women. Novel agents designed to modulate abnormal growth factor signaling in and around the BC cell further
increase patients’ chances of survival. However, both conventional chemotherapeutic agents as well as some of the
novel signaling inhibitors can induce important cardiovascular side-effects, potentially attenuating the progress made
in recent years. The mechanism of cancer drug-induced cardiovascular complications varies greatly with some
compounds inducing irreversible myocardial cell damage, while others lead to temporary cell dysfunction. The
challenge of the future will be to prospectively discriminate between irreversible damage which can lead to progressive
cardiovascular disease and reversible cardiovascular dysfunctions without further prognostic implications. Since
adjuvant therapy for BC is potentially curative, emphasis must be placed on finding treatments combining maximum
efficacy with the minimum of long-term side-effects in order to achieve survival with preserved quality of life.
Key words: anthracyclines, breast cancer, cardio-oncology, cardiotoxicity, trastuzumab, tyrosine kinase inhibitors
introduction
The introduction of adjuvant anticancer therapy
[anthracyclines, taxanes and, for patients with human
epidermal growth factor receptor 2 (HER2)-positive disease,
trastuzumab and lapatinib] considerably improved both
disease-free survival (DFS) and overall survival (OS) in women
with operable early breast cancer (EBC) [1–4]. Early detection
is thought to have contributed roughly equally to the evident
steady reduction in age-standardized BC death rates over the
past two decades [5]. In the UK, mortality fell 40% from 1989
to 2006 [6], and in the United States, by 28% from 1990 to
2000 [5]. Age-adjusted 5-year survival among European
women diagnosed with BC from 2000 to 2002 is now 79% [7].
methods
Despite the fact that growing patient numbers are cured with modern
adjuvant therapy, disease relapse and death, as well as short- and long-term
toxic effects including treatment-related malignancies and heart failure
(HF) still occur. Minimizing delayed toxic effects is of crucial importance in
potentially curative treatment. Therefore, the search for more effective and
less toxic adjuvant regimens continues. With increasing understanding of
BC, individualization of therapy based on specific tumor characteristics is
warranted.
Experience from metastatic trials raised concerns that were rapidly
incorporated into design of adjuvant trials. One important insight was
that targeted agents needed to be used in combination with conventional
agents or, alternatively, with other novel agents. Table 1 summarizes
current novel agent adjuvant phase III trials [8]. In addition, pertuzumab
and other multi-targeted compounds already in registration studies for use
in first-line metastatic BC are likely to be investigated in the adjuvant
setting soon.
Some of these newer agents have inherent cardiac and/or cardiovascular
toxicity. Certain pathways targeted in the tumor cell (such as HER2) are
also present in the heart [9]. Preclinical work suggests that the HER2/erbB2
system may modulate the effects of oxidative stress in the cardiac myocyte;
these agents therefore require further study with regard to implications of
cardiotoxicity [10, 11]. This paper describes the known cardiovascular side-
effects of cytotoxic and targeted drugs used in adjuvant BC therapy. Our
understanding of risk factors for cardiotoxicity and developments in
imaging and biomarkers which may prove helpful in identifying and
managing these problems in our patients will also be addressed.
unique myocardial characteristics
The heart is a post-mitotic organ and has only limited ability
to recover cell loss. Additionally, myocardial tissue lacks
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the enzyme catalase and thus demonstrates reduced capacity to
handle oxidative stress, as may be caused or furthered by
anthracyclines, hypertension or other cardiac conditions that
may be considered cardiac risk factors. Oxidative stress changes
the equilibrium between protein degradation and synthesis and,
when pronounced, also activates caspases that induce myocyte
apoptosis or necrosis [12].
The heart, however, has extensive reserves and can
accommodate considerable myocyte loss. When clinically
relevant cardiac dysfunction is observed, cardiac reserves
are substantially exhausted; clinical deterioration from that
point may be in an accelerated phase, and deterioration
may be precipitous. Since decreased left ventricular
ejection fraction (LVEF) ensues only after full
compensation is no longer achieved, maintained LV function
as measured by cardiac ultrasound or nuclear techniques
should be considered neither as an indicator of normal
myocardium nor as an evidence of an absence of
cardiotoxicity [13]. Early damage may not be recognized by
these parameters, and biomarkers have not yet been
incorporated into the routine clinical setting but may have
considerable potential.
targeted anticancer agents may also target the
heart
Activation of the HER2 signaling pathways in cardiomyocytes
appears to modulate cell adaptation with regard to
environmental stressors and to promote cell survival [14]. Mice
with ventricle-restricted deletion of the HER2 gene
demonstrate spontaneous LV failure as the mature respond
poorly to additional stress and to have myocytes that are
particularly susceptible to anthracycline toxicity [9]. While
there is little evidence, the idea that HER2 inhibition can
potentiate the effects of oxidative stressors could explain, at
least in part, the synergy between the cardiotoxic effects of
trastuzumab and anthracyclines first apparent with their
concurrent use in the metastatic setting [15].
LV dysfunction associated with specific
therapies
anthracyclines
Anthracyclines are highly effective in the treatment of a variety
of solid and hematologic malignancies, and they remain
Table 1. Current phase III adjuvant and neoadjuvant trials in breast cancer involving novel agents
Acronym Population Regimens
BETH (NSABP) N+ or high-risk N2 TCH or T-FEC followed by trastuzumab to 1 year
versus above plus bevacizumab for 1 year
SOLD (Finnish Breast Cancer Group) N+ or high-risk N2 T-FEC with 9 weeks trastuzumab during T versus above
plus post-FEC trastuzumab to 1 year
ALTTO (BIG–TCBI) Anthracycline-taxane-based chemotherapy plus one of
four options: trastuzumab 1 year versus lapatinib 1
year versus trastuzumab then lapatinib versus
trastuzumab plus lapatinib
BEATRICE (Roche) Triple negative Anthracycline plus/minus taxane or taxane only versus
above plus bevacizumab for 1 year
ECOG 5103 (ECOG) N+ or high-risk N2 AC followed by paclitaxel versus AC plus bevacizumab
followed by paclitaxel plus bevacizumab ·4 versus
treatment as in second arm followed by bevacizumab
·10
USO 06090 Various, depending on ER/PR status TC versus TAC versus TC–bevacizumab
Gepar Quinto (GBG) HER2-negative EC with or without bevacizumab followed in
responders by T plus/minus bevacizumab and in
nonresponders by paclitaxel plus/minus everolimus
(RAD 001)
HER2-positive EC-T trastuzumab versus lapatinib, followed by
postoperative adjuvant trastuzumab for 1 year
Neo-ALTTO (BIG–TCBI) HER2-positive Lapatinib 1500 mg versus trastuzumab versus lapatinib
1000 mg plus trastuzumab, all plus paclitaxel, and
with further randomization post surgery
NSABP B41 HER2-positive AC followed by wP plus lapatinib versus wP plus
trastuzumab versus wP plus lapatinib plus trastuzumab
followed by 1 year trastuzumab after surgery
CALGB 40601 HER2-positive wP plus lapatinib versus wP plus trastuzumab versus wP
plus lapatinib plus trastuzumab followed after surgery by
dose-dense AC and then 1 year trastuzumab
N+/2, node positive/negative; TCH; docetaxel plus carboplatin plus trastuzumab; T, docetaxel; FEC, fluorouracil, epirubicin, cyclophosphamide; AC,
doxorubicin plus cyclophosphamide; ER, estrogen receptor; PR, progesterone receptor; C, carboplatin; HER2, human epidermal growth factor receptor 2;
wP, weekly paclitaxel.
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a frequently utilized group of drugs in BC treatment in both the
metastatic and the adjuvant setting. Of continuing concern,
however, is that specter of cardiotoxicity, especially in the
adjuvant setting, where many of the patients have been made
disease free as a result of their prior treatment [13, 16, 17].
Anthracycline cardiotoxicity is a form of irreversible non-
ischemic toxic cardiomyopathy. In the most extreme form, the
entity leads to severe LV systolic dysfunction and HF, which
may be progressive, which carries a poor long-term prognosis
and which can result in cardiac death. Acute manifestations
that appear at the time of exposure may include troponin
elevation, electrocardiogram changes, dysrhythmia and,
occasionally, myopericarditis. Biopsy specimens in this period
confirm early myocyte damage despite preserved LVEF [18].
More typically, anthracycline cardiotoxicity presents as LV
dysfunction months or years after exposure; analogous to other
forms of progressive HF, it is assumed that considerable
remodeling and compensatory mechanisms have been invoked.
When severe, even late anthracycline cardiotoxicity may
progress to advanced HF and end-stage heart disease.
Anthracycline cardiotoxicity is related to the cumulative dose
administered. Initially, in case of doxorubicin, it was estimated
that a cumulative dose of 500 mg/m2 correlated with
a likelihood of developing HF of 5%. [19] More recent
retrospective analyses suggest that doxorubicin cardiotoxicity
occurred at cumulative dosages considerably lower than first
appreciated and that the cumulative dosage that correlated with
a 5% incidence of HF ranged between 400 and 450 mg/m2 [20].
Lower cumulative dosages are used in the adjuvant setting and
the fact that women without preexisting heart disease were
entered into these trials yielded an estimated HF likelihood
of 2.2%. Long-term effects of adjuvant anthracycline
treatment are still being explored, and the final incidence may
be somewhat higher than these estimations. Long-term follow-
up in Belgian patients treated with adjuvant epirubicin
demonstrates that higher anthracycline dosages result in better
oncologic event-free survival, but at the cost of additional
cardiotoxicity; the overall oncologic effectiveness was
equivalent to that seen in the combination chemotherapy with
cyclophosphamide, methotrexate and fluorouracil regimens
[21]. The French Adjuvant Study Group found a possible
association between a higher dose of fluorouracil, epirubicin
and cyclophosphamide (FEC) (100 versus 50 mg epirubicin)
with HF and asymptomatic LV dysfunction, but the oncologic
survival benefit probably outweighed the risks [22]. A recent
Cochrane meta-analysis of five trials with doxorubicin and
epirubicin found a nonsignificant difference in the clinical HF
in favor of epirubicin [relative risk (RR) 0.36, 95% confidence
interval (CI) 0.12–1.11] [23].
Since the 1980s, a marked decrease in cumulative
anthracycline exposure has taken place and has reduced the
incidence of associated cardiotoxicity. Nevertheless, some
myocyte damage occurs even at low dosages and renders
patients more susceptible to the development of HF when
sequential stresses are encountered [13]. Recent evidence from
the SEER database on routine use in >40 000 women suggests
an ongoing appreciable problem, at least in more elderly
patients [24]. Among women aged 66–70 years diagnosed with
stages I–III BC from 1992 to 2002, the adjusted hazard ratio
(HR) for HF in patients treated with adjuvant anthracyclines
compared with non-anthracyclines was 1.26 (95% CI 1.12–
1.42). Cumulative HF incidence at 10 years was 38% after
anthracyclines, 32.5% after non-anthracyclines and 29%
without chemotherapy. These differences become more
pronounced with longer follow-up. HF rate was higher in
patients who received anthracyclines, even after excluding
elderly and those with significant comorbidities, than was the
case when other agents were utilized. Age is a well-known
risk factor for anthracyclines, and, not surprisingly, the
likelihood of HF almost doubled with each 10-year increase in
age. Other significant baseline predictors of increased risk were
peripheral and coronary artery disease (HRs 1.31 and 1.58,
respectively), diabetes (HR 1.74), hypertension (HR 1.45) as
well as emphysema and chronic bronchitis (HR 1.68).
Trastuzumab, given in <3% of those treated with
chemotherapy, was significantly associated with HF risk (HR
1.44); however many of these patients recover cardiac function.
Left-sided irradiation of the chest was not a risk factor,
probably reflecting improved techniques minimizing cardiac
radiation dose. Two recent comparable studies reported an
increased risk of HF and valve dysfunction in irradiated BC
patients as well as higher rates of myocardial infarction and
coronary artery disease associated with radiation involving the
left hemithorax [25, 26].
trastuzumab
The addition of trastuzumab to adjuvant therapy reduces the
risk of BC recurrence at 3 years nearly by half and improves
survival by around a third [2–4, 27]. However, major trials
consistently show an increased relative risk of New York Heart
Association (NYHA) class III–IV HF, with incidence ranging
from 0 to 3.9% [28]. The risk of cardiac dysfunction increases
at lower levels of baseline LVEF, with higher cumulative dose
of anthracyclines given before trastuzumab, and at advanced
age; the incidence is also increased with current or previous use
of antihypertensive agents and a higher body mass index [14].
Interestingly, much of the cardiotoxicity associated with
trastuzumab when given following an anthracycline is
reversible.
Cardiotoxicity is relatively rare with trastuzumab as
monotherapy [29]. The toxicity is unrelated to cumulative dose
and largely reversible. In the HERA trial with sequential
chemotherapy and trastuzumab, the majority of patients with
cardiac dysfunction recovered within 6 months [30]. Longer
term follow-up of these patients showed that trastuzumab-
associated cardiac dysfunction predominantly occurs during
trastuzumab treatment (in contrast to anthracycline cardiac
toxicity which frequently becomes manifest months to years
after the initial treatment) [31]. Furthermore, reexposure to
trastuzumab after recovery from LV dysfunction is generally
well tolerated [32]. In the major adjuvant BC trials, which
included >10 000 patients randomly assigned to receive
trastuzumab, only one cardiac death was reported compared
with two in the control arms. Based on growing evidence,
a distinction can be made between Type I and Type II
cardiotoxicity, whereby Type I reflects the scenario of damage
associated with myocyte death; Type II is more benign and is
associated with cell hibernation or myocardial stunning (Table 2).
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There is certainly an additive and possibly synergistic
interaction between anthracyclines and trastuzumab. It is likely
that despite preserved LVEF after anthracycline therapy, some
degree of cardiac damage has occurred and compensatory
mechanisms have been recruited. Trastuzumab then constitutes
a form of sequential stress on an already compromised heart.
Alternatively, trastuzumab could prevent the myocyte’s
adaptive response to or repair of the anthracycline injury,
further compounding the oxidative damage [34]. This
mechanism could explain the distinctly higher incidence of
cardiotoxicity in concurrent use of trastuzumab and
anthracyclines [35]. Taken together, data from metastatic and
adjuvant trastuzumab trials suggest that a longer interval
between anthracycline treatment and trastuzumab reduces the
risk of cardiomyopathy, but this has not been evaluated
prospectively [27]. Concurrent use of anthracyclines and
trastuzumab should therefore be preferably confined to clinical
trials [14].
lapatinib
Lapatinib inhibits both EGFR and HER2 kinases. Perez et al.
[36] prospectively evaluated LVEF in 3689 patients (69% in
BC) who received lapatinib (alone or in combination) in the
course of 44 phase I–III studies. No cardiac deaths were
attributed to lapatinib; significant HF occurred in 0.2% of
patients and 1.4% had an asymptomatic decline in LVEF of >20
percentage points. This less stringent criteria for cardiac
impairment suggests that the incidence may have been
underestimated; lack of standardization of cardiotoxicity
criteria makes comparison of outcome across studies more
difficult. Notwithstanding these concerns, of the patients with
cardiac events, 88% recovered to some degree, suggesting that
lapatinib is an agent exhibiting the Type II form of cardiac
impairment.
In this series, cardiac events were not substantially influenced
by prior therapy; overall cardiac event rate was 1.6%, in 2.2% of
patients with prior anthracyclines exposure and in 1.7% of
patients who had received trastuzumab. It should be noted,
however, that the population treated with lapatinib may have
included patients who tolerated trastuzumab. Additionally,
a relatively long interval between anthracycline and subsequent
lapatinib treatment may have allowed further recovery of the
anthracycline injury. Data from 274 patients who received
lapatinib for >6 months do not suggest cumulative, dose-
related cardiotoxicity, but longer follow-up is needed. The
ongoing adjuvant phase III ALLTO trial comparing the efficacy
and safety of lapatinib, trastuzumab and both will provide more
definitive information on relative cardiotoxicity.
In a second study, patients with advanced HER2-positive BC
and normal LVEF were randomly assigned to receive lapatinib
plus capecitabine or capecitabine alone [37]. All had previously
been exposed to an anthracycline, a taxane and trastuzumab.
There was no symptomatic LVEF in either group.
bevacizumab
In metastatic BC, an anti-angiogenic strategy is proven to be
beneficial [38, 39]. At least five major ongoing adjuvant or
neoadjuvant trials in BC (three in HER2-negative disease) now
include bevacizumab. Cardiovascular monitoring is a crucial
element in these studies given evidence that hypertension,
arterial thromboembolism and HF are among the potentially
serious toxic effects of bevacizumab [40]. Early data from
a phase II trial on feasibility of incorporating bevacizumab into
an adjuvant regimen of dose-dense doxorubicin and
cyclophosphamide followed by paclitaxel suggest that 10% of
patients experience a >10% decline in LVEF after eight cycles
[41]. Hypertension with secondary LV dysfunction, rather than
primary myocardial toxicity, may play a part in this decline,
and further study is required to clarify the relative contribution
of these factors.
sunitinib and sorafenib
The multi-targeted tyrosine kinase inhibitors (TKIs) sunitinib
and sorafenib, which inhibit both angiogenesis and tumor
growth pathways, have been extensively used in advanced BC
trials. Whereas the sunitinib phase III SUN program in BC
has recently been stopped due to futility of reaching the
primary end point in several trials, sorafenib is still under
development. Recently, a phase IIb study evaluating sorafenib
combined with capecitabine in patients with locally advanced
BC reported no unexpected side-effects [42]. In a study of
sunitinib in a series of 75 patients with gastrointestinal
stromal tumors, 28% had an absolute LVEF reduction of at
least 10% and 8% developed HF [43]. Schmidinger et al. [44]
reported symptomatic cardiotoxicity in 18% of 74 renal cancer
patients treated with sunitinib or sorafenib. Prompt treatment
led to recovery in all cases and allowed anticancer treatment to
continue. The reversibility of the cardiotoxicity suggests that
sunitinib and sorafenib are Type II agents. However,
cardiotoxicity in routine practice (particularly with sunitinib)
may be more frequent than is reported in clinical trials [44, 45].
In a recent review, the data for placebo and sunitinib arms
were reviewed and demonstrated elevation of blood pressure in
the sunitinib group with partial resolution between cycles.
Fifteen instances of hypertensive crises were noted among 243
patents in the treatment arms, while no instances of
hypertensive crises were seen in the 118 patients on the placebo
arms [46].
other cardiovascular toxic effects
hypertension
BC and hypertension are often comorbid conditions, as both
more commonly affect older populations. Underlying
Table 2. Clinical features distinguishing Type I and Type II
cardiotoxicity [33]
Type I (e.g. doxorubicin) Type II (e.g. trastuzumab)
Predominant cell death Cell dysfunction
Typical anthracycline biopsy No anthracycline-like changes on
biopsy
Cumulative and dose related Not cumulative or dose related
Permanent damage Generally reversible
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hypertension and/or antihypertensive therapy increases risk for
anthracycline- and trastuzumab-related LV systolic dysfunction
(see below). The anti-angiogenic agents bevacizumab, sunitinib
and sorafenib also are associated with significant systemic
hypertension with a reported incidence as high as one-third of
the patients and considered partly responsible for the modest
risk of LV dysfunction [43, 47, 48]. The mechanism is thought
to involve VEGF inhibition [49]. Serious complications such as
stroke are rare but have been reported.
ischemia
A number of anticancer agents are associated with myocardial
ischemia and rarely infarction. Among those commonly used
are 5-fluorouracil [50, 51] and the pro-drug capecitabine.
Myocardial ischemia, however, is more prevalent with
continuous infusions of 5-fluorouracil rather than with the
bolus administration which forms part of adjuvant BC
chemotherapy and as such is very rarely a problem in clinical
practice. These agents probably induce ischemia through
coronary artery spasm, and ischemia is more frequently
encountered in those with preexisting coronary artery disease.
Other agents that may be associated with cardiac ischemia
include paclitaxel and docetaxel, but ischemia is rare following
the use of these agents. Bevacizumab has been associated with
systemic arterial thrombotic events, with a reported incidence
of 3.8%; these have included predominantly myocardial
infarction, angina, stroke and transient ischemic attack. Risk
factors included prior arterial thromboembolic events and
age >65 years [52].
dysrhythmia
Paclitaxel has been associated with sinus bradycardia and
various degrees of heart block; these episodes are self-limited
and usually do not require alteration of the therapeutic
regimen; no malignant arrhythmias have yet been reported [53].
Arsenic trioxide has been associated with QT prolongation, and
patients on that agent should be monitored; other drugs that
may further prolong the QT interval, including certain
antiemetics and antimicrobials, should be used with increased
caution and with consideration of serial monitoring of the QTc.
assessing cardiac risk and monitoring
for toxicity
history and physical examination: when should
alarm bells ring?
A detailed clinical assessment is essential in identifying
individuals at risk for cardiovascular complications of cancer
treatment (see Table 3). In addition, a careful assessment of
current functional capacity, volume status and blood pressure
is required. Patients at particular risk of cardiotoxicity should
have cardiac evaluation that should be carried out in
conjunction with the oncologist so that the choice of therapy
may be optimized. Risk factors to be considered are included in
Table 3, but other factors that could contribute to cardiac stress
should not be ignored. Whenever possible, risk factors should
be modified or reduced by treating elevated blood pressure,
normalizing lipids, encouraging weight reduction and smoking
cessation.
imaging
Echocardiography is widely available and relatively inexpensive
and hence is often the initial investigation of choice for
evaluating systolic function. Reproducibility has generally
improved over the last decade. Several relatively small studies
with conflicting results have looked at various
echocardiographic parameters to evaluate earlier and more
sensitive indicators of chemotherapy-related cardiomyopathy.
These included the Tei index [54], tissue Doppler
measurements [55], myocardial strain [56] and dobutamine
stress echocardiography [57]. Further validation of these
techniques is required before incorporating them into
monitoring algorithms.
Alternatively, radionuclide ventriculography or Multiple
Gated Acquisition scan (MUGA) is frequently used and is less
subject to observer variability; it involves exposure to radiation
and is associated with higher cost. Nuclear imaging is difficult
in patients with arrhythmias. Choice between
echocardiography versus MUGA can be individualized but is
often based on provider preference or regional practice
patterns. As the two measurements are not interchangeable, the
same technique should be used for serial measurements in
a given patient whenever possible.
biomarkers
A rise in troponin I, a marker of cell death, may precede
measurable changes in LVEF, and B-type natriuretic peptide
(BNP), associated with myocardial stretch, is a marker for
volume overload. BNP can increase when filling pressures rise
even with normal LVEF. Despite inconsistent evidence, both
markers seem potentially sensitive indicators of treatment-
related cardiac disease. There is some evidence that early release
of troponin I predicts later LV dysfunction following
anthracycline chemotherapy [58]. Follow-up of patients treated
for childhood cancers has established that levels of plasma
N-terminal brain natriuretic peptide (NT pro-BNP) are
abnormally raised in some asymptomatic survivors [59].
Elevated levels were related to cumulative anthracycline
exposure and to end-diastolic LV diameter. Ongoing trials that
Table 3. Risk factors for cardiomyopathy
Established risk factors for anthracycline cardiomyopathy include
Prior anthracycline exposure regardless of agent or administration
regimen
Mediastinal radiation
Age >65 years or very young
Hypertension
Exposure to other cardiotoxic agents such as cyclophosphamide, taxanes
or trastuzumab
Established risk factors for trastuzumab-related cardiac dysfunction include
Exposure to anthracyclines (worse with higher cumulative dose) and
taxanes
Age >50 years
Antihypertensive medications
Borderline left ventricular ejection fraction
Increased body mass index
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incorporate these markers should help place their clinical
application in better perspective [13].
tools for reducing risk of cardiotoxicity
cardioprotection
There has been considerable interest in dexrazoxane as
a potential means of reducing anthracycline cardiotoxicity.
However, based on a review of current evidence, the American
Society of Clinical Oncology advises against routine use of
dexrazoxane in adjuvant BC therapy [60]. There is also a clear
rationale for liposomal formulations of doxorubicin based on
more favorable pharmacokinetics and tissue distribution as well
as evidence from the metastatic setting that cardiotoxicity is
reduced while antitumor efficacy is maintained [61, 62].
limiting anthracycline exposure
Given the risk of cardiotoxicity associated with anthracyclines,
treatment regimens reducing exposure to these agents are being
actively debated. Modern adjuvant treatment regimens
generally limit the cumulative doxorubicin dose to 300 mg/m2
and several recent trials are addressing non-anthracycline
regimens in the adjuvant setting. Other strategies included
identification of patient subsets responding more or less
favorably to anthracyclines in order to individualize therapy. In
a retrospective analysis, Gennari et al. [63] demonstrated that
the benefits of anthracycline-containing adjuvant chemotherapy
are confined to the minority of women whose tumors
overexpress or amplify HER2. Pooled data from eight studies
involving >3000 women with HER2-negative disease showed
that DFS and OS were almost identical with anthracycline- and
non-anthracycline-based regimens. Anthracycline sensitivity of
HER2-positive disease may therefore be not due to HER2 per se
but to amplification of the topoisomerase (topo) IIa gene
located nearby on chromosome 17 [64].
More recent data, however, do not support this hypothesis. A
meta-analysis using data from randomized trials of 2000
patients showed that HER2 and topo IIa genes were of clinically
modest and statistically borderline value in predicting
sensitivity to anthracyclines. In a recent analysis of a large
randomized trial, no association between HER2 or topo IIa
status and efficacy of adjuvant anthracycline-based treatment
was found. Furthermore, data from the neoadjuvant setting
suggest that high rates of pathological complete response can be
achieved by standard anthracycline-based regimens in patients
with triple negative disease, i.e. in the absence of HER2
positivity [65]. Given current uncertainties, the
recommendation to use HER2 or topoisomerase IIa as
a predictive tool is premature.
In the PACS 01 trial, a sequential regimen of three cycles FEC
followed by three cycles docetaxel achieved a significantly
higher rate of 5-year DFS and OS than six cycles FEC in women
with node-positive EBC [66]. The taxane-containing regimen
was associated with significantly fewer severe cardiac adverse
events (0.4% vs 1.3% in the FEC ·6 arm). The most recent
follow-up of USO trial 9735 demonstrated an OS of 87% with
four cycles of adjuvant docetaxel plus cyclophosphamide (TC)
versus 82% with doxorubicin plus cyclophosphamide (AC) at
7 years [67]. The non-anthracycline regimen also achieved
a significantly higher DFS. These intriguing data (not yet
confirmed) represent a shift in management as they show
potential benefit for TC in all relevant subgroups. Yet,
comparative trials of TC against state-of-the-art three-drug
anthracycline-containing combinations (e.g. USO trial 06090 in
the United States, PlanB or SUCCESS C trials in Germany) are
still ongoing.
Given these data, docetaxel/cyclophosphamide can be
considered for women at risk for cardiotoxicity and in HER2-
positive patients when chemotherapy is to be followed by
trastuzumab. In a combined analysis of the pivotal B31/
NCCTG data, 6.7% of the patients treated with anthracyclines
experienced a large enough drop in LVEF to preclude planned
trastuzumab treatment [2]. The BCIRG 006 trial compared
anthracycline plus cyclophosphamide followed by docetaxel
plus trastuzumab (AC-TH) against docetaxel plus carboplatin
plus trastuzumab (TCH). At the third interim analysis, both
regimens had comparable DFS (84% versus 81%) and OS rates
(92% and 91%) at 5 years [68]. Compared with TCH, AC-TH
was associated with four to five times more NYHA class III–IV
HF and twice >10% drop in LVEF. This greater LVEF reduction
was evident even after 4 years. The final report of this
important trial is eagerly awaited.
screening, monitoring and avoidance of other risk
factors
There is still no established consensus about cardiac monitoring
during anthracycline chemotherapy. An approach, based on the
preferences of the authors, is provided in Table 4. Uncertainties
related to cardiotoxicity are reflected in current guidelines and
prescribing information generally based on protocols in the
major trastuzumab trials [27,69–72]. It is recommended that
LVEF be assessed before starting an anthracycline, before
starting trastuzumab, every 3–6 months during therapy and
Table 4. Proposal/recommendations for cardiac monitoring
Thorough cardiac assessment including baseline LVEF, before starting
treatment
Reassessment after 300 mg/m2 of doxorubicin or equivalent; after every one
to two cycles if additional anthracycline is given
Follow-up LVEF measurements: 3–6 months following completion of
therapy and then yearly for 5 years
Higher risk individuals, especially if LVEF has decreased >15% from
baseline or to <45%, may be monitored more frequently
In case of anthracycline-related cardiomyopathy at any time during or
following treatment, further anthracycline should be avoided (or after
careful consideration of the risks)
In patients with comorbidities or diagnostic findings at risk for
cardiotoxicity, anthracycline-free adjuvant chemotherapy can be
considered, particularly if additional therapy with targeted agents is
planned
If potentially cardiotoxic treatment is indicated, all other sources of
oxidative stress should, whenever possible, be avoided and volume status
optimized
LVEF, left ventricular ejection fraction.
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every 6–12 months for at least 2 years following cessation. If
trastuzumab is withheld because of a decline in ventricular
function, LVEF should be assessed more frequently. When
trastuzumab is used without an anthracycline, less intensive
monitoring is acceptable. In case of other agents and regimens,
protocols are less clear. For a summary of reported incidences
of cardiotoxicities for breast cancer drugs refer to Table 5.
treatment of cardiovascular dysfunction
The treatment of asymptomatic LV dysfunction and HF caused
by cancer treatment has not been adequately studied. When
the causative agent is associated with cell death, treatment
should be similar to that utilized in managing the traditional
forms of HF. Initially a b-adrenergic blocker and/or an
angiotensine converting enzyme (ACE) inhibitor may be
employed if the LVEF is <45%; judicious use of diuretics and
dietary sodium restriction to maintain euvolemia and careful
control of risk factors such as hypertension should be
incorporated into the treatment plan. Pharmacotherapy should
be long term to prevent LV remodeling and progressive HF.
When the reduced LVEF is likely to be reversible, it should be
reevaluated after 1 month free of the agent. LVEF remaining
<45% should be considered for treatment, although data on
long-term benefit of such intervention are not available.
interruption and resumption of anticancer
treatment
Trastuzumab should be suspended if LVEF drops >15
percentage points from baseline or >10 percentage points to
a value below the lower limit of normal. The measurement
should be repeated after 4–6 weeks. If LVEF improves or rises
above the lower limit of normal, restarting trastuzumab may be
considered. The policy on rechallenge should be adjusted
according to the individual patient’s risk of relapse; in cases of
HER2-positive disease, adjuvant trastuzumab substantially
increases the chance of cure and, therefore, the threshold for
stopping it permanently should be high. If substantial
anthracycline-associated cardiotoxicity occurs, these agents
should not be resumed. Long-term cardiac follow-up by will
depend on the individual patient’s cardiac risk. A distinction
can be made between agents with a demonstrated long-term
risk of HF and those with unknown long-term risk.
discussion
Anticancer drugs have a range of potential cardiotoxicities. Of
greatest concern in adjuvant BC therapy are anthracyclines and
trastuzumab with fundamental differences regarding pathologic
findings, clinical features and prognosis. Noteworthy is that
established risks are based on data from clinical trials conducted
in very select populations. The true problem of cardiotoxicity in
routine clinical practice may therefore be underestimated.
The challenge presently is maintaining the efficacy of BC
treatment while considering cardiac risk varying between
patients and with different treatment options. Gianni et al. [14]
estimate that up to 2 million women in the United States have
been treated with anthracyclines and are at risk of developing
delayed cardiac damage. HF with anthracycline regimens can
occur long after treatment ends. Moreover, even very common
adjuvant endocrine therapies, particularly in postmenopausal
women may also contribute to the expression of underlying
cardiovascular disease or expose the heart to additional toxic
effects [74]. Minimizing long-term toxicity is important given
the rising number of patients whose life expectancy is
approaching that of those without BC. For the afflicted patient,
HF is a devastating and sometimes fatal event. For society, it is
a significant additional drain on health resources. Nevertheless,
exaggerated concern for cardiotoxicity should not lead to
inappropriate withdrawal of valuable therapy.
Our greater understanding of BC is increasing, and
cardiologists are distinguishing between the seemingly irreversible
cardiotoxicity due to cumulative exposure to anthracyclines, and
the reversible, non-dose-related toxicity seen with trastuzumab.
New cardiac imaging techniques and biomarkers should enable
more accurate monitoring of the short-term treatment-related
cardiac effects. Cardiac care in the future is likely to become more
complex. The combined effects of a multiplicity of oncology
interventions, longer durations of treatment using targeted
agents, and an aging population mean that the number of cancer
patients with cardiac problems will increase. Optimizing cardiac
health requires oncologists, cardiologists and family doctors to
promote lifestyle changes such as smoking cessation, weight loss,
healthy diet and regular exercise.
Cardiologists and oncologists have a shared interest in
ensuring that today’s cancer survivors do not become
tomorrow’s heart patients, and the two specialties are already
cooperating in developing guidelines (e.g. proposed by the
Canadian Trastuzumab Working Group) [28]. Cardiologists
stand ready to help in advising on treatment, in monitoring its
effects, in dealing with cardiac problems that arise and in
deciding when treatment constitutes a substantially increased
cardiac risk. They need encouragement to develop expertise in
the area. Whether there is a need for a formal subspecialty of
cardio-oncology remains an open question. But there is no
doubt that a key to effective management will be
communication and collaboration between oncologists and
cardiologists within a multidisciplinary cancer team.
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Table 5. Incidence of cardiotoxicities with breast cancer drugsa
Left ventricular dysfunction Ischemia
Doxorubicin 5b Nr
Epirubicin 0.9%–3.3% Nr
Paclitaxel Nr <1%–5%
Docetaxel 2.3%–8% 1.7%
Trastuzumab 2%–28% Nr
Bevacizumab 1.7%–3% 0.6%–1.5%
Sunitinib 2.7%–11% Nr
aAdapted from Yeh et al. [73].
bAt a cumulative dose of 400–450 mg/m2; considerably higher at larger
cumulative dosages.
Nr, not reported.
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